Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24894887 | 0.89 | GRM2 (0.44) | GRM2GRM3KDM4E | |
| SCHEMBL29197107 | 0.89 | GRM2 (0.44) | GRM2GRM3KDM4E | |
| SCHEMBL25195654 | 0.89 | GRM2 (0.44) | GRM2GRM3KDM4E | |
| SCHEMBL23073770 | 0.82 | TSHR (0.45) | GRM2GRM3ALDH1A1KDM4ETSHR | |
| SCHEMBL356301 | 0.82 | SMO (0.42) | GRM2GRM3KDM4ECHRM4CXCR3 | |
| SCHEMBL9989341 | 0.82 | KDM4E (0.39) | GRM2GRM3ALDH1A1KDM4ECXCR3 | |
| SCHEMBL29197417 | 0.80 | GRM2 (0.39) | GRM2GRM3ALDH1A1MAPK1TSHR | |
| SCHEMBL29197287 | 0.80 | GRM2 (0.39) | GRM2GRM3ALDH1A1MAPK1TSHR | |
| SCHEMBL29197283 | 0.80 | GRM2 (0.39) | GRM2GRM3ALDH1A1MAPK1TSHR | |
| SCHEMBL950845 | 0.79 | GRM2 (0.43) | GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336627-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES | AC IMMUNE SA (CH) | 2024-10-10 | — | — | US | disclosed |
| CN-117940435-A | Novel compounds for diagnosing TDP-43 proteinopathies | AC免疫有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023285661-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES | AC IMMUNE SA (CH) | 2023-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336627-A1 | NOVEL COMPOUNDS FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHIES | TARDBP, FUS, MAPT | GRM2 245/4885GRM3 148/4885ALDH1A1 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.